p53 mutation as a genetic trait of typical medullary breast carcinoma
p53 mutation as a genetic trait of typical medullary breast carcinoma
复制标题
DOI：
10.1093/jnci/91.7.641
复制
发表时间：
1999-04-07
期刊：
影响因子：
--
通讯作者：
Soussi, T
中科院分区：
文献类型：
--
作者：
de Cremoux, P;Salomon, AV;Soussi, T
髓样癌是一种分化较差的乳腺癌，组织学分级高，预后好。它只占所有乳腺癌的5%(1-3)。到目前为止，只有组织学标准被用来定义这种肿瘤类型；还没有发现遗传特征。在20%-40%的浸润性乳腺癌中发现了p53基因(也称为TP53)的变化，但其在髓样乳腺癌中的状态鲜有文献报道。免疫化学检测肿瘤细胞核中稳定的突变型p53是最方便的方法，但这种检测结果与测序等分子分析结果的相关性并不完全一致(4)。乳腺癌中P53基因突变的频率约为20%，但免疫组织化学分析发现30%-40%的肿瘤中有P53基因积聚
Medullary carcinoma is a poorly differentiated breast cancer tumor with a high histologic grade and a paradoxically good prognosis. It accounts for only 5% of all breast cancers (1–3). Thus far, only histologic criteria are used to define this tumor type; no genetic characteristics have been identified. An alteration in the p53 gene (also known as TP53) is found in 20%–40% of invasive breast cancers, but its status in medullary breast cancer is poorly documented. Immunochemical detection of a stable mutant p53 in nuclei of tumor cells is the most convenient assay, but the correlation of the results from such an assay with results from molecular analysis, such as sequencing, is not totally in agreement (4). The frequency of p53 mutations in breast cancer is around 20%, but immunohistochemical analysis detects p53 accumulation in 30%–40% of tumors